Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Nuclear factor erythroid 2-related factor 1 (NFE2L1, also commonly referred to as Nrf1) is a cap 'n' collar basic-leucine zipper (bZIP) transcription factor that plays a critical role in maintaining cellular proteostasis, redox balance, and lipid metabolism. Under basal conditions, NFE2L1 is anchored to the endoplasmic reticulum (ER) membrane and constitutively degraded via the ER-associated degradation (ERAD) pathway. However, in response to proteasome inhibition or oxidative stress, NFE2L1 escapes degradation, undergoes proteolytic cleavage by the protease DDI2, and translocates to the nucleus. Once in the nucleus, it heterodimerizes with small Maf proteins to bind antioxidant response elements (AREs), driving the transcription of proteasome subunits, deubiquitinating enzymes, and antioxidant genes. This compensatory mechanism, known as the 'bounce-back' response, is a major driver of resistance to proteasome inhibitors (such as bortezomib and carfilzomib) in multiple myeloma and solid tumors, making NFE2L1 inhibition a promising strategy to sensitize cancer cells to chemotherapy. Conversely, pharmacological activation of NFE2L1 (using investigational compounds like RUN-89) represents a therapeutic avenue for neurodegenerative diseases, such as Alzheimer's and Parkinson's, where enhancing proteasomal clearance can mitigate the accumulation of toxic protein aggregates.
Pharmacological modulation of NFE2L1 involves either activation or inhibition. Activators (such as RUN-89) stimulate NFE2L1-dependent transcription of proteasome subunits and chaperones to clear protein aggregates in neurodegenerative diseases. Inhibitors of NFE2L1 or its processing machinery (such as DDI2 inhibitors like nelfinavir, p97 inhibitors like NMS-873, or transcriptional suppressors like doxorubicin) block the NFE2L1-mediated 'bounce-back' response, thereby sensitizing cancer cells to proteasome inhibitors.
13 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Nuclear factor erythroid 2-related factor 1 (NFE2L1).